|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 318.80 USD | -1.11% |
|
-2.51% | -19.76% |
| 03-05 | Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement | CI |
| 03-05 | Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments | RE |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 48.07x | 19.14x | 0.26x | 7.05x | 33.76x | 35.04x | -.--% | 42.76B | ||
| 29.43x | 18.14x | 0.61x | 11.08x | 22.26x | 23.61x | 0.66% | 895B | ||
| 25.86x | 6.71x | -1.78x | 6.02x | 16.39x | 18.1x | 2.17% | 587B | ||
| 24.65x | 71.18x | 0.08x | 6.75x | 13.55x | 13.9x | 3.05% | 401B | ||
| 18.04x | 6.31x | 1.14x | 4.39x | 10.87x | 12.31x | 3% | 345B | ||
| 21.41x | 6.33x | 11.74x | 5.76x | 14.24x | 15.24x | 2.81% | 300B | ||
| 24.8x | 5.63x | 1.15x | 5.16x | 14.3x | 15.34x | 1.69% | 306B | ||
| 27.37x | 5.12x | -0.66x | 4.79x | 14.99x | 17.7x | 2.88% | 289B | ||
| 25.26x | 16.96x | 5.66x | 6.39x | 11.37x | 14.52x | 2.67% | 202B | ||
| 20.59x | 6.98x | 3.22x | 6.26x | 11.33x | 13.34x | 2.19% | 184B | ||
| 11.53x | 5x | -1.64x | 4.21x | 8.77x | 10.18x | 4.36% | 171B | ||
| 12.7x | 1.69x | 0.22x | 3.21x | 7.68x | 9.1x | 6.47% | 154B | ||
| 12.02x | 5.25x | 0.27x | 3.16x | 8.51x | 9.13x | 4.18% | 122B | ||
| 28.43x | 5.6x | 1.94x | 8.63x | 19.26x | 20x | -.--% | 127B | ||
| 12.95x | 4.4x | 1x | 2.8x | 8.1x | 9.31x | 3.36% | 111B | ||
| 12.02x | 1.18x | -15.64x | 2.2x | 7.25x | 7.88x | 5.55% | 107B | ||
| 36.6x | 7.91x | 3.49x | 11.85x | 23.28x | 24.82x | 2.66% | 99.37B | ||
| 51.56x | 1.29x | 0.83x | 2.86x | 10.61x | 30.14x | 3.5% | 57.28B | ||
| 43.5x | 6.16x | 1.45x | 10.19x | 34.46x | 35.83x | 0.47% | 54.53B | ||
| 21.18x | 2.02x | 1.74x | 3.68x | 14.56x | 16.3x | 1.9% | 44.71B | ||
| Average | 25.40x | 10.15x | 0.75x | 5.82x | 15.28x | 17.59x | 2.68% | 230.12B | |
| Weighted average by Cap. | 24.38x | 14.33x | 0.95x | 6.61x | 15.39x | 17.04x | 2.4% |
- Stock Market
- Equities
- ALNY Stock
- Sector Alnylam Pharmaceuticals, Inc.
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















